In turn, the knockdown gene expression profile of TRAF3, which is an inhibitor of the NFκB pathway, is associated with better survival and better immune checkpoint blockade response in primary cancer-treated patients having immune checkpoint blockade therapy (33). The gene discussed is NFKB1; the disease is cancer.